KEYNOTE-087五年随访:帕博利珠单抗单药治疗复发或难治性经典型霍奇金淋巴瘤
KEYNOTE-087是一项2期试验,评估帕博利珠单抗单药治疗复发或难治性经典型霍奇金淋巴瘤的长期疗效与安全性。中位随访63.7个月,客观缓解率71.4%,完全缓解率27.6%,中位缓解持续时间16.6个月,中位无进展生存期13.7个月,中位总生存期未达到。20例接受第二疗程帕博利珠单抗的患者中,19例可评估者客观缓解率73.7%。
要点
- 中位随访63.7个月,客观缓解率71.4%,完全缓解率27.6%,部分缓解率43.8%。
- 中位缓解持续时间16.6个月,中位无进展生存期13.7个月,中位总生存期未达到。
- 第二疗程帕博利珠单抗在19例可评估患者中客观缓解率73.7%,中位缓解持续时间15.2个月。
核心结论
- 单药帕博利珠单抗可诱导持久的缓解,尤其是在达到完全缓解的患者中。
- 第二疗程帕博利珠单抗在初始完全缓解后复发的患者中常能再次诱导持续缓解。
研究设计与样本
- 2期KEYNOTE-087试验(NCT02453594),患者接受帕博利珠单抗治疗不超过2年。
- 患者为复发或难治性经典型霍奇金淋巴瘤,分为3个队列:队列1为自体干细胞移植后和维布妥昔单抗治疗后进展;队列2为挽救化疗和维布妥昔单抗治疗后未行自体干细胞移植;队列3为自体干细胞移植后未后续维布妥昔单抗。
- 达到完全缓解后停药并随后出现进展的患者有资格接受第二疗程帕博利珠单抗。
- 主要终点为盲法中心评估的客观缓解率和安全性。
主要发现
- 中位随访63.7个月,客观缓解率71.4%(95%CI 64.8-77.4),完全缓解率27.6%,部分缓解率43.8%。
- 中位缓解持续时间16.6个月,中位无进展生存期13.7个月,中位总生存期未达到。
- 四分之一缓解者(包括一半完全缓解者)维持缓解≥4年。
- 20例接受第二疗程帕博利珠单抗,19例可评估者客观缓解率73.7%(95%CI 48.8-90.8),中位缓解持续时间15.2个月。
- 任何级别治疗相关不良事件发生率72.9%,3级或4级不良事件发生率12.9%,无治疗相关死亡。
临床怎么用
- 单药帕博利珠单抗可诱导持久缓解,尤其在达到完全缓解的患者中。
- 第二疗程帕博利珠单抗在初始完全缓解后复发的患者中常能再次诱导持续缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). However, long-term response durability and outcome of patients who receive a second course after treatment discontinuation after complete response (CR) remain of clinical interest. We present KEYNOTE-087 data after >5 years of median follow-up. Patients with R/R cHL and progressive disease (PD) after autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV; cohort 1), salvage chemotherapy and BV without ASCT (cohort 2), or ASCT without subsequent BV (cohort 3), received pembrolizumab for ≤2 years. Patients in CR who discontinued treatment and subsequently experienced PD were eligible for second-course pembrolizumab. Primary end points were the objective response rate (ORR) using blinded central review and safety. The median follow-up was 63.7 months. ORR was 71.4% (95% confidence interval [CI], 64.8-77.4; CR, 27.6%; partial response, 43.8%). Median duration of response (DOR) was 16.6 months; median progression-free survival was 13.7 months. A quarter of responders, including half of complete responders, maintained a response for ≥4 years. Median overall survival was not achieved. Among 20 patients receiving second-course pembrolizumab, ORR for 19 evaluable patients was 73.7% (95% CI, 48.8-90.8); median DOR was 15.2 months. Any-grade treatment-related adverse events occurred in 72.9% of patients and grade 3 or 4 adverse events occurred in 12.9% of patients; no treatment-related deaths occurred. Single-agent pembrolizumab can induce durable responses, particularly in patients achieving CR. Second-course pembrolizumab frequently reinduced sustained responses after relapse from initial CR.
引用
- Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023. PMID: 37319435. doi:10.1182/blood.2022019386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。